Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 8, 2025
Ligand Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …
Syndax Announces Participation in May Investor Conferences
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …
Aptose Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat …
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
GlobeNewswire
·
May 8, 2025
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …
Entrada Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 …
Verano Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) ("Verano" or the "Company"), a leading multi-state cannabis company, today announced its financial results for the first quarter ended March 31, 2025, which were …
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
GlobeNewswire
·
May 8, 2025
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, …
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 8, 2025
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced …
Aveanna Healthcare Holdings Announces First Quarter Financial Results and Revised 2025 Outlook
GlobeNewswire
·
May 8, 2025
First Quarter Revenue was $559.2 million, a 14.0% increase over the prior year period Gross margin increased 25.9% to $183.6 million compared to Q1 2024 First Quarter Net income was $5.2 million compared to net loss of $11.2 million for the comparable …
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
GlobeNewswire
·
May 8, 2025
– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians …
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
GlobeNewswire
·
May 8, 2025
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b …
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
GlobeNewswire
·
May 8, 2025
Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER) EBITDA(1) of € 270.2 million, +10.7%, margin on revenue of 39.7% Adjusted net income(2) of € …
Privia Health Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Strong First Quarter Performance and Operating Execution Enters the State of Arizona Full-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges for All Metrics with Attributed Lives Unchanged ARLINGTON, Va., May 08, 2025 (GLOBE NEWSWIRE) -- …
Dentsply Sirona Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impact GAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per share Adjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, …
Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 8, 2025
SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results …
Enovis Announces First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective …
NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm for Development and Manufacture of Adeno-Associated Virus (AAV) Therapeutics
GlobeNewswire
·
May 8, 2025
Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across multiple AAV programs LAUSANNE, …